Article Information
History
- December 5, 2022.
Article Versions
- Version 1 (November 14, 2022 - 11:01).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Grant Johnson1,2,
- Branden S.J. Gregorchuk3,
- Arek Zubrzycki1,
- Kurt Kolsun3,4,
- Adrienne F.A. Meyers3,5,
- Paul A. Sandstrom3,5 and
- Michael G. Becker3,4,*
- 1Laboratory Medicine and Infection Prevention and Control, Lakeridge Health, Oshawa, Ontario, Canada
- 2Ontario Tech University, Oshawa, Ontario, Canada
- 3National HIV and Retrovirology Laboratories, National Microbiology Laboratory Branch, JC Wilt Infectious, Diseases Research Centre, Public Health Agency of Canada, Winnipeg, Canada
- 4Department of Microbiology, University of Manitoba, Winnipeg, Canada
- 5Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada
- ↵*Correspondence: michael.glen.becker{at}phac-aspc.gc.ca
Posted December 05, 2022.
Clinical Evaluation of the GeneXpert® Xpert® Xpress SARS-CoV-2/Flu/RSV PLUS Combination Test
